Inactive Instrument

Other languages Apricus Biosciences Inc Nasdaq

Equities

US03832V1098

End-of-day quote Nasdaq Other stock markets
- ^USD	-

16/05	Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	CI
14/05	Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	17/05
Reverse Split: 1 of 8	16/05	FA
Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	16/05
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	14/05
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split	14/05
Seelos: Q1 Earnings Snapshot	14/05
Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Seelos Therapeutics, Inc. Announces Resignation of Daniel J. O?Connor from the Board	04/05
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations	29/04
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	29/04
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19/03
Seelos Therapeutics' ALS treatment fails in mid-stage study	19/03
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)	19/03
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	19/03
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	04/03
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	04/03
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	29/01
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	26/01
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	26/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Apricus Biosciences Inc Nasdaq

Equities

US03832V1098

Other languages

Filters